External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Citação
DIABETES OBESITY & METABOLISM, v.23, n.4, p.971-979, 2021
Resumo
Aim: To investigate the external validity of recent antihyperglycaemic trials evaluating cardiovascular outcomes in a multimorbid population. Materials and Methods: Selection criteria of 15 randomized controlled trials from the 2020 American Diabetes Association Standard of Care statement were applied in a stepwise manner to tertiary care patients with type 2 diabetes. Primary outcomes were the number of patients eligible per individual trial and for the aggregate of trials. Secondary outcomes included patient predictors of trial eligibility. Results: Of 1059 patients, the mean (SD) age was 66 (10.74) years, the median (IQR) Charlson index was 2 (2, 3) and 458 (43%) had documented cardiovascular disease. The median (IQR) number of patients included in individual trials was 263 (174.25-308.75) and 795 (75.1%) of them were eligible for at least one trial. Among those 264 ineligible, 127 (48.1%) had an HbA1c level of 7% or less and no cardiovascular disease; 53.5% and 34.4% of the patients were eligible for two and three different classes of drugs, respectively. The strongest predictor of trial eligibility was cardiovascular disease (risk ratio 2.17, 95% CI 2.01-2.35). Conclusions: A considerable proportion of multimorbid patients would be eligible for recent antihyperglycaemic trials. This positive finding can be attributed to development guidance in diabetes trials and the different approach we took, in which we evaluated inclusion by trials as an aggregate.
Palavras-chave
antidiabetic drug, canagliflozin, cardiovascular disease, DPP-4 inhibitor, GLP-1, insulin analogues
Referências
- Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS111, DOI [10.2337/dc20-S010, 10.2337/dc20-s010]
- American Diabetes Association, 2020, Diabetes Care, V43, pS98, DOI 10.2337/dc20-S009
- [Anonymous], 2015, DIABETES CARE, V38, pS49, DOI 10.2337/dc15-S011
- [Anonymous], 2015, DIABETES CARE, V38, pS41, DOI 10.2337/dc15-S010
- Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2
- Battaglia S, 2015, RESPIRATION, V89, P383, DOI 10.1159/000375314
- Blonde L, 2018, ADV THER, V35, P1763, DOI 10.1007/s12325-018-0805-y
- Canivell S, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/2018374
- Carvalho JTG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179540
- Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642
- Deruaz-Luyet A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013664
- Fortin M, 2006, ANN FAM MED, V4, P104, DOI 10.1370/afm.516
- Gerstein HC, 2019, LANCET, V394, P121, DOI 10.1016/S0140-6736(19)31149-3
- Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352
- Hanlon P, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1427-1
- Hernandez AF, 2018, LANCET, V392, P1519, DOI 10.1016/S0140-6736(18)32261-X
- Holman RR, 2017, NEW ENGL J MED, V377, P1228, DOI 10.1056/NEJMoa1612917
- Husain M, 2019, NEW ENGL J MED, V381, P841, DOI 10.1056/NEJMoa1901118
- IDF, 2019, IDF DIABETES ATLAS
- Kennedy-Martin T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1023-4
- Kosiborod M, 2017, CIRCULATION, V136, P249, DOI 10.1161/CIRCULATIONAHA.117.029190
- Marso SP, 2017, NEW ENGL J MED, V377, P723, DOI 10.1056/NEJMoa1615692
- Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI 10.1056/NEJMoa1603827
- Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69
- Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
- Nielsen SF, 2013, NEW ENGL J MED, V368, P576, DOI 10.1056/NEJMc1214827
- Pati S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183966
- Pfeffer MA, 2015, NEW ENGL J MED, V373, P2247, DOI 10.1056/NEJMoa1509225
- Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078
- Rosenstock J, 2019, JAMA-J AM MED ASSOC, V321, P69, DOI 10.1001/jama.2018.18269
- Rothwell PM, 2005, LANCET, V365, P82, DOI 10.1016/S0140-6736(04)17670-8
- Rubin DB, 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]
- Saunders C, 2013, DIABETIC MED, V30, P300, DOI 10.1111/dme.12047
- Scichilone N, 2014, RESPIRATION, V87, P11, DOI 10.1159/000355082
- Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
- Shao SC, 2019, BMJ OPEN DIABETES
- Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837
- U.S. Food and Drug Administration, GUID IND DIAB MELL E
- US Food and Drug Administration, TYP 2 DIAB MELL EV S
- van Buuren S, 2011, J STAT SOFTW, V45, P1
- White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889
- Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389
- Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720